Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Muris sends “apologies to Spike Lee”

This article was originally published in The Tan Sheet

Executive Summary

In speech entitled "Do The Right Thing" FTC Chairman Timothy Muris urges cable TV execs to screen weight-loss product ads for obviously deceptive claims. "Our goal is not to require television-network style clearance procedures for weight loss ads," but rather to focus on "the most egregious examples...miracle herbs that claim consumers can eat whatever they want and still lose weight," or "physically implausible" claims, Muris noted at Cable Television Advertising Bureau conference in New York Feb. 11. Vetting would not have to include diets, exercise plans or clinical studies, he added. Noting that "some claim that screening will increase their exposure to tort liability," Muris maintained, "that dog won't hunt. We will send you a list of claims [in the near future] that scientists state are not scientifically feasible"...

You may also be interested in...

Teva CEO Schultz: ‘Proof Is In The Pudding’ For US Biosimilars

Teva CEO Kåre Schultz believes his prediction is coming true for the Truxima biosimilar in-licensed from Celltrion, as he gave the latest update on Teva’s efforts to settle significant legal issues around the US opioid crisis.

EU Notified Body Association Takes Steps To Allay EC’s Virtual Audit Fears

The European Commission has reluctantly allowed virtual audits in the context of new MDR and IVDR. The EU notified body association is helping the collective effort to meet its strict requirements.

New UK Biosimilars Pathway Suffers Setback

The UK’s implementation of a new national licensing framework for biosimilars has been pushed back from the start of 2021, with the MHRA citing “intense COVID-19 activities” as the cause of an indefinite delay in the consultation process.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts